



HumanIC - Human - Centric Indoor Climate for Healthcare Facilities

Project 101119726

Individualized support to the doctoral student

INTRODUCTION

Patricia Muñoz, MD PhD

pmunoz@hggm.es; patricia.munoz.garcia@salud.madrid.org; pacmunoz@ucm.es

Clinical Microbiology and Infectious diseases

Hospital General Universitario Gregorio Marañón

Research institute Gregorio Marañón

Centro de investigación biomédica en red en Enfermedades Respiratorias (CIBERES)

University Complutense of Madrid, Spain



HumanIC project has received funding from the European Union's Horizon Europe research and innovation program under the Marie Skłodowska-Curie (HORIZON-MSCA-2022-DN-01, project no 101119726)

Funded by
the European Union



Welcome & Objectives

- **Meeting objectives:** personalized mentorship. Support supervisors and doctoral graduates integrate:
 - in clinical settings
 - into different future workplaces
- The experience of Clinical Microbiology/Infectious Diseases physicians.

Why This Topic Matters

- Importance of mentorship for **academic success**
 - **Identifying** and building on each student's **unique competences**
 - **Encouraging** self-assessment and reflection
- Increasing **diversity** in doctoral pathways
- **Clinical settings** present unique supervision challenges

Impact of individualized support



Academic success



Emotional well-being



Professional growth

If not....



Higher levels of stress

Isolation

**High dropout rates in PhD
programs**





Which doctoral students need more individualized support?

- Doctoral candidates with **nontraditional paths**
 - **Diverse** academic, cultural or professional backgrounds
 - **More interdisciplinary, flexible, or clinical-academic** tracks
- Trend towards **customized supervision** approaches
 - **Competency-based** vs. time-based progress
 - **Individualized learning plans** in doctoral education



Hospital and University



Facultad Medicina, Universidad
Complutense Madrid. UCM




Hospital General Universitario Gregorio
Marañón

Multidisciplinary research



- Co-authors institutions



- Co-authors speciality



Web of Science



Funded by
the European Union

Individual Development Plans

Communication Styles & Tools

- Transparent, respectful, timely dialogue
- Use of logs, shared calendars, supervision contracts

Expectations & Boundaries

- Clarifying roles
- Time commitments, meeting norms, availability



Mentoring in Clinical Microbiology

Jesús Guinea
Clinical Microbiology and Infectious Diseases
jguineaortega@yahoo.es

Mentoring in Clinical Microbiology



- Jesús Guinea:
 - Degree in Pharmacy (1996)
 - Clinical Microbiology Training (2002)
 - PhD in Microbiology (2005)
 - Research activity on Clinical Mycology (2002-present)
 - Gregorio Marañón teaching hospital

Mentoring in Clinical Microbiology



TRANSLATIONAL RESEARCH

HumanIC project has received funding from the European Union's Horizon Europe research and innovation program under the Marie Skłodowska-Curie (HORIZON-MSCA-2022-DN-01, project no 101119726)

Mentoring in Clinical Microbiology


Why do we need to research on clinical microbiology?

- Epidemiology of infections
- Diagnosis of infections
- Factors predisposing to infections
- Species involved in infections
- Detection of resistance
- Clinical outcomes (treatment and management)
- Environmental sources (niches of pathogens, outbreaks)

We firmly believe that by doing that, we can offer a better care to patients in the long term



Mentoring in Clinical Microbiology



Mentoring in Clinical Microbiology



Getting a PhD takes a lot of effort
You will have to work extra-hours
You will get frustrated
You will be tempted to give up

And you may ask yourself, "Well, how did I get here?"
Once in a lifetime (Talking Heads)



But it is really worth doing and inspiring
It's like crossing the finish line after a marathon

What a student must have learnt when completing their PhD



Let's do not forget that we are training new scientists

CORE COMPETENCES

- How to read a paper on clinical microbiology
- How to detect an area or topic of potential interest
- How to elaborate a scientific question
- How to engineer and design a scientific study
- How to perform data analysis (including statistics)
- How to transform raw data into deliverable information (tables, graphs, etc.)
- How to prepare an abstract for a scientific meeting (and present at the meeting if accepted)
- How to write a paper (and get it accepted in a journal!)
- How to write the PhD document
- How to give a speech (particularly important to defend the PhD)
- How to draft a scientific project
- Paperwork (ethics committee, hospital permissions, funder follow-up, etc)

Steps in guiding a PhD student

The importance of the topic

- Why is it important/relevant?
- Define well the subject to study on
- Basic bibliography
- Survey the literature and update relevant articles

Engineering the PhD project

- Outline the study objectives
- Assessment of resources
- Weaknesses and strengths
- Chronology of the project

Demand to mentor 95%

Steps in guiding a PhD student



Initial training (1-6 months)

- Learn basic laboratory tools to carry out the project
- Get familiar with the team dynamics
- Problem solving (promote independence to find out solutions)
- Demand to mentor 80%

Steps in guiding a PhD student



Mid training (7-36 months). Experimental part

- Carry out the experimental part of the project
- Data analysis
- Periodic supervising (to detect potential deviations)
- Demand to mentor 20%

Steps in guiding a PhD student



Mid training (7-36 months). Data delivery. Scientific meetings

- Opportunity to report preliminary data:
 - Training in poster drafting
 - Training in oral presentations
- Opportunity to discuss your results with colleagues
- Meeting with relevant scientists on your field
- Update your knowledge and news about your topic

Steps in guiding a PhD student

Mid training (7-36 months). Data delivery. Scientific meetings

- Set policy of (outstanding) meetings attendance



- Our PhD students attend at least one international meeting during their training period (commonly three times)

Rezafungin showed high *in vitro* activity and very low resistance rate against a collection of yeasts causing fungaemia in patients admitted to a tertiary hospital in Madrid from 2014 to 2024

Pilar Escrbano^{1,2,3}, Ana Gómez^{1,2}, Almudena Burillo^{1,2,4}, Patricia Muñoz^{1,2,4,5}, Jesús Guinea^{1,2,3,4}
¹Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain; ²Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; ³Faculty of Health Science - HM Hospitals, Universidad Camilo José Cela, Madrid, Spain; ⁴Medicine Department, Faculty of Medicine, Universidad Complutense de Madrid, Madrid, Spain; ⁵CIBER Enfermedades Respiratorias - CIBERES (CB06/06/0058), Madrid, Spain

Background

Rezafungin is a new echinocandin recently launched and approved for the treatment of invasive candidiasis/candidemia
 EUCAST has recently released specific recommendations for rezafungin susceptibility testing and set clinical breakpoints, but data generated at different institutions is needed, particularly before the drug use in the hospital setting

Objective

We studied the susceptibility of a collection of blood culture fungaemia isolates to rezafungin and assessed the rate of antifungal resistance to the drug

Materials and Methods

Incident fungaemia yeasts isolates (n=537)
 525 patients; 12 patients had mixed fungaemia
 Gregorio Marañón Hospital (Madrid, Spain)
 January 2014 to October 2024
 Rezafungin activity was studied by the EUCAST E.Def 7.4 procedure; Tween 20 was added into the broth medium
 Minimum inhibitory concentration (MIC) was defined as the lowest concentration reaching $\geq 50\%$ of fungal growth inhibition compared to the drug-free control well; breakpoints were used to assess the percentage of resistance (Table 1)

Results

- Species distribution of isolates and rezafungin MIC distributions against the isolates studied are shown in Table 1

Table 1. Isolates tested and rezafungin MIC distributions

Species (no. of isolates)	Rezafungin MICs (mg/L)																
	≤ 0.0002	0.0005	0.001	0.002	0.004	0.008	0.016	0.03	0.06	0.125	0.25	0.5	1	2	4	8	≥ 32
<i>C. albicans</i> complex (n=232)	25	60	134	8	3	2	0	0	0	0	0	0	0	0	0	0	-
<i>C. parapsilosis</i> complex (n=141)	0	0	0	0	0	0	0	0	0	0	0	0	4	24	53	57	-
<i>C. glabrata</i> complex (n=82)	0	0	0	0	10	69	0	0	2	0	0	0	0	0	1	0	-
<i>C. tropicalis</i> (n=37)	0	0	0	0	1	30	6	0	0	0	0	0	0	0	0	0	-
<i>C. krusei</i> (n=18)	0	0	0	1	1	7	9	0	0	0	0	0	0	0	0	0	-
<i>C. dubliniensis</i> (n=4)	0	0	1	0	2	0	1	0	0	0	0	0	0	0	0	0	-
Other <i>Candida</i> spp (n=11)	1	0	0	0	2	1	1	0	0	0	2	4	0	0	0	0	-
Non- <i>Candida</i> spp (n=12)	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	4	5

Cells with the "—" symbol indicate non-tested antifungal concentrations; Underlined values indicate non-wild type isolates according to clinical breakpoints; Values in bold indicate modal MIC values

- Rezafungin MIC values against *C. albicans* were very low and many isolates showed MIC values equal to or lower than the lowest concentration tested (0.0002 mg/L)
- Only three *C. glabrata* isolates were rezafungin-resistant, which represented 3.7% of *C. glabrata* isolates tested, were also anidulafungin and micafungin resistant, and harboured *FKS* gene substitutions (Table 2)

- MIC values against *C. parapsilosis* were higher, whereas MIC values against *C. glabrata*, *C. tropicalis*, and *C. krusei* were in between

- In vitro* activity against non-*Candida* spp isolates was very limited

- Considering the clinical breakpoints, all *C. albicans*, *C. parapsilosis*, *C. tropicalis*, *C. krusei*, and *C. dubliniensis* isolates were rezafungin-susceptible

Conclusions

Rezafungin showed a high *in vitro* activity against most of isolates in which clinical breakpoints are available. We only detected resistance in a small proportion of *FKS*-mutant *C. glabrata* isolates which showed cross resistance with the older echinocandins

The study was supported by grant P122/20005 and an unrestricted grant from Mundipharma Ltd
 The study was co-funded by the European Regional Development Fund (FEDER) 'A way of making Europe'



E0234

Congress of the European Society of Clinical Microbiology and Infectious Diseases

ESCMID Global

P2907



National survey on azole-resistant clinical *Aspergillus fumigatus* collected in 2023: environmentally generated azole resistant isolates (TR₃₄-L98H and TR₄₆-Y121F-T289A substitutions) are expanding across Spain

Pilar Escrbano^{1,2,3}, Jesús Moraga^{1,2}, Ana Gómez^{1,2}, Patricia Muñoz^{1,2,4,5}, Jesús Guinea^{1,2,3,4} on behalf of the ASPEIN study group


¹Hospital General Universitario Gregorio Marañón - Madrid (Spain); ²Instituto de Investigación Sanitaria Gregorio Marañón - Madrid (Spain); ³School of Health Sciences - HM Hospitals, Camilo José Cela University - Madrid (Spain); ⁴CIBER Enfermedades Respiratorias - CIBERES (CB06/06/0058) - Madrid (Spain); ⁵Medicine Department, School of Medicine, Universidad Complutense de Madrid (Spain)

Background

We started out a surveillance program on azole resistance in *Aspergillus fumigatus* in Spain in 2019 and the rate of resistance found (7.4%) was mostly confirmed (6.4%) in a second survey conducted in 2022

We here report azole resistance in *A. fumigatus* data derived from the third national survey conducted in 2023

Material and Methods



Results

- Isolates distributed as fully antifungal susceptible (n=901, 92.8%) or resistant to one or more antifungal agent (n=70, 7.2%) which involved *A. fumigatus sensu stricto*, n=40, *A. lentulus*, n=21, *A. fumigatiformis*, n=7, *A. fennelliae*, n=1, and *A. felis*, n=1


Table. Azoles and amphotericin B MIC distributions and percentage of resistance in *A. fumigatus* complex isolates

	MIC distributions (number of isolates at each MIC, in µg/L)											Resistance	
	0.036	0.06	0.06	0.125	0.25	0.5	1	2	4	8	≥ 16	No. of isolates (%)	
A. fumigatus sensu stricto (n=971)													
Amphotericin B			5	34	452	400	50	5	6	7	11	29 (3.0%)	
Isavuconazole	2	2	7	171	612	112	15	6	4	2	30	50 (5.1%)	
Voriconazole				5	107	573	220	14	19	9	10	66 (6.8%)	
Posaconazole	7	134	593	177	27	21	8	2			2	47 (4.9%)	
Isavuconazole	1	4	4	17	350	448	48	7	20	12	62	82 (8.4%)	
A. fumigatus sensu stricto (n=943)													
Amphotericin B			5	34	452	400	50					0 (0%)	
Isavuconazole	2	2	7	170	609	107	11	3		30	53	53 (5.6%)	
Voriconazole				5	107	573	218	13	22	9	10	58 (6.1%)	
Posaconazole	7	133	592	166	10	21	8	2			2	35 (3.7%)	
Isavuconazole	1	4	4	17	348	446	27	2	20	12	56	78 (8.3%)	
Cryptic species (n=98)													
Amphotericin B	1						5	6	7	11	29	58 (5.9%)	
Isavuconazole			1	3	5	4	3	4	2	8	17	35 (3.6%)	
Voriconazole						2	11	17				28 (2.9%)	
Posaconazole	1	1	11	17								22 (2.2%)	
Isavuconazole						2	2	21	5			26 (2.6%)	

Values shaded in grey indicate MICs within the area of technical uncertainty (ATU) translated as resistant isolates as follows: posaconazole (*A. fumigatus sensu stricto* [n=14072], *A. fumigatus sensu stricto* [n=2172], cryptic species [n=1272], *A. fumigatus sensu stricto* [n=23486], *A. fumigatus sensu stricto* [n=1272], cryptic species [n=21722]). Values in bold indicate resistant isolates according to EUCAST clinical breakpoints (table v.10.0)

- Isolates harbouring the TR₃₄-L98H or TR₄₆-Y121F-T289A substitutions were detected in patients admitted to 15 hospitals located in seven regions. The presence of such isolates had been already reported in six regions (Madrid, Catalonia, Castilla León, Castilla La Mancha, Valencia, and Andalusia) in previous surveys whereas a new region (Balearic Islands) is here added to the list (Figure)

Figure. Map showing the cities where the 73 hospitals providing with *A. fumigatus* complex isolates were located



Conclusions

- Up to 7% of *A. fumigatus* complex Spanish isolates collected in 2023 were azole-resistant, a steady resistance rate being reported in Spain since 2019
- Environmentally generated azole-resistant isolates (TR₃₄-L98H or TR₄₆-Y121F-T289A *cyp51A* gene substitutions) involved 75% of all *A. fumigatus sensu stricto* resistant isolates and seem to be more prevalent in some areas

The study was supported by grant P121/00450 from Fondo de Investigación Sanitaria (IS, Instituto de Salud Carlos III) and an unrestricted grant from Glend Ltd. The study was co-funded by the European Regional Development Fund (FEDER) 'A way of making Europe'



Congress of the European Society of Clinical Microbiology and Infectious Diseases

Steps in guiding a PhD student



Mid training (7-36 months). Data delivery. Publications

- As a rule of thumb:
 - Posters/oral presentations should be turned into **Papers**
- Choose the most appropriate journal (aim 1st quartile journals)
- Objectives of the thesis (one objective – one paper)
- Our PhD students publish about 7-8 papers as part of their PhD projects
- Demand to mentor 95%

Steps in guiding a PhD student



Mid training (7-36 months). Data delivery. Publications

- Drafting a paper is one of the most difficult tasks PhD students face!
- My experience is that PhD students get the doctorate but fail to get enough competences to draft scientific papers
- Procrastination is quite common and must be early detected
- Paper production pace should be kept from year 2 to 4
- Paper production is key to get a further post-doc position

Steps in guiding a PhD student



Mid training (7-36 months). Data delivery. Publications

INTRODUCTION

MATERIAL & METHODS

RESULTS

DISCUSSION

CONCLUSIONS

Steps in guiding a PhD student



Late training (37-48 months). PhD defence

- Year 4 should be allocated to publish the latest publications, drafting the PhD document, and thesis defence
- Papers should be backbone of the document
- Discussion of the document also takes some time
- Preparation of defence (and questions during defence)
- Demand to mentor 70%



HumanIC - Human - Centric Indoor Climate for Healthcare Facilities

Project 101119726

Individualized support to the doctoral student

IN THE CLINICAL SETTING

Patricia Muñoz, MD PhD

pmunoz@hggm.es; patricia.munoz.garcia@salud.madrid.org; pacmunoz@ucm.es

Clinical Microbiology and Infectious diseases

Hospital General Universitario Gregorio Marañón

Research institute Gregorio Marañón

Centro de investigación biomédica en red en Enfermedades Respiratorias (CIBERES)

University Complutense of Madrid, Spain



HumanIC project has received funding from the European Union's Horizon Europe research and innovation program under the Marie Skłodowska-Curie (HORIZON-MSCA-2022-DN-01, project no 101119726)

Funded by
the European Union

Content



MY OWN JOURNEY



THE HOSPITAL



**RELATIONSHIP DOCTORATE
STUDENT - SUPERVISOR**

Content



HOSPITAL & STUDENT DIVERSITY

Understanding student diversity



- **Diverse backgrounds, diverse needs**
 - Clinical practitioners, international students, early-career researchers
 - Varying motivations, experiences, and academic goals
- **Learning & working styles**
 - Balancing workplace and academic responsibilities
 - Independent vs. collaborative learners

"Career Anchors" by Edgar Schein

1. Technical/Functional Competence
2. General Managerial Competence
3. Autonomy/Independence
4. Security/Stability
5. Entrepreneurial Creativity
6. Service/Dedication to a Cause
7. Pure Challenge
8. Lifestyle



<https://psycho-tests.com/test/sheins-career-anchors>



Funded by
the European Union

What truly drives your career decisions


Anchor	Core Motivation
Technical/Functional	Mastery in a specific skill or profession
General Managerial	Leadership, decision-making, and organizational control
Autonomy/Independence	Freedom to define how and when you work
Security/Stability	Job security and predictable future
Entrepreneurial Creativity	Innovating and building something new
Service/Dedication to a Cause	Making a meaningful difference for others
Pure Challenge	Solving tough problems, testing personal limits
Lifestyle	Harmonizing career with personal life priorities



Understand your strengths and choose the options that will bring inner satisfaction from work

What type of
leader is your
supervisor?

And you?



<https://career minds.com/blog/knowning-disc-profile>

Other aspects to consider

- **Cultural & ethical sensitivities**
 - Avoid assumptions about student experience
 - Different ethical standards across cultures
 - Sensitivity to biases in clinical care and research
 - Multicultural teams and supervision
- **Mental health & burnout risks**
 - Long hours, emotional intensity, impostor syndrome
 - Supervisor's role in identifying stress and burnout signals
 - *Also supervisor is at risk!!!!*

Clinicians undertaking a PhD

Challenges in Clinical Environments

- Often **part-time** basis off-campus, balancing research with patient care
- Time-managing, integrating into the research environment and developing an academic identity
- Navigating institutional and regulatory constraints
- Not so many people with PhD around

Which is the main motivation?

- Contact a group to get some research training?
- Get a job in the hospital?
- Or really want to know how to conduct research and prepare a PhD? Get your career in a new direction

Very high rate of dropouts



Practical tips

1. Help your student **feel part** of the team and **university**
2. **Identity shift** (from skilled clinician to student) and tethered **autonomy**
3. Know each other's **boundaries**
4. Help your student **use their time** well
5. Exploit the student **clinical skills** (interviews, assessments, professionalism..)
6. Get to know your hashtags (*#phdchat; #AcademicChatter; #phdlife; #AcademicTwitter; #phdchatter; #phdweekend; #parttimephd*)
7. **Be clear on expectations** (productivity, rules, conflict management)
8. Funding
9. Monitor **progress**
10. Prepare for setbacks and **delays**
11. Don't underestimate the power of informal supports
12. Career and future planning



Different backgrounds are also found in the clinical setting

Backgrounds different from physicians

Biologist, Pharmacist, Food Technician,
Engineer



Practical tips for non physicians

1. You need to understand the language
2. You need to really understand the problem
3. You need to understand physician's minds and priorities



Bridge the Cultural Gap

- **Learn the language:**
 - Clinicians often speak in shorthand—medical acronyms, clinical urgency
 - Patient-first logic
 - Keep a glossary and ask questions often. Understand and communicate.
- **Respect rhythms:** Hospitals run at a different pace.
 - Be patient with scheduling and be mindful of clinical priorities.
 - Get to understand the hospital and all its problems.
- **Attend clinical meetings:** Observing how doctors make decisions helps you align your research goals with real medical needs.
 - You need the necessary background. Patients and families are behind.





Clarify/Align Your Research Scope

- **Translate tech into clinical value:**
 - Always ask yourself, “How would this help a doctor, nurse, or patient?”
 - CONTRIBUTE TO THE ORGANIZATION
- **Get feedback early:**
 - Share initial prototypes or conceptual frameworks with clinicians—they'll help catch unrealistic assumptions fast
- **Simplify without dumbing down:**
 - Explain your work in a way that engages non-engineers without losing its scientific integrity





Manage Stress Proactively



- **Define what success looks like**—for both yourself and your clinical collaborators
 - Not just publication count
- **Set communication boundaries:**
 - It's okay to not respond instantly to every request
 - Define availability clearly
- **Find allies:**
 - Connect with other researchers embedded in clinical environments—they've probably felt the same kind of overwhelm



Use Tools That Help You Adapt

- **Visualization software** to make abstract ideas more accessible.
- **Shared digital workspaces** like hospital-approved cloud drives to foster collaboration.
 - Confidentiality is KEY. Informed consents.
Hospital protocols
- **Versioned documentation** so you can show how your thinking evolved based on clinical feedback





RELATIONSHIP

DOCTORATE STUDENT - SUPERVISOR

Individualized support, OF COURSE



But ... a coin has two sides

- The role of a doctoral supervisor is NOT to treat students like children or constantly monitor their emotional states
- Our responsibility lies in **fostering academic growth, critical thinking, and independent research**
- At this stage, we already are two professionals



The PhD student's world revolves around one thesis, while the **CLINICAL** supervisor's daily reality is a whirlwind of mentoring, healing, teaching, researching, reporting and managing

Your supervisor is not only yours, and probably you are not the priority



Bidirectional relationship


Student

- Joyful enthusiasm
- Mutual trust
- Committed work
- Open communication
- Intellectual stimulation



Supervisor

- Shared experience
- Supportive guidance
- Role modeling
- Support learning
- **Psychological safety**



Leadership

What People Get Wrong About Psychological Safety

Six misconceptions that have led organizations astray. by Amy C.
Edmondson and Michaela J. Kerrissey

From the Magazine (May-June 2025)





6 Key Misconceptions about **psychological safety**


1. **Means Being Nice**— True psychological safety allows for respectful disagreement, not just comfort
 2. **Means Getting Your Way**— Safety supports candor, not consensus
 3. **Means Job Security**— It's about openness, not immunity from consequences
 4. **Requires a Trade-Off with Performance**— In fact, it enables higher performance through learning and innovation
 5. **Is a Policy or checklist** — It's a dynamic team culture, not a static rule
 6. **It's top-down only** — Everyone contributes to building it, not just leaders
- ✅ **What It Really Means:** A shared belief that it's safe to speak up, ask questions, and admit mistakes—without fear of humiliation or punishment

Message for PhD students: **You are at the steering wheel**

You are a true profesional in the field, no longer in a junior role

You are in control. You deserve to be here, in high-education world

- Set agendas, meetings, timelines
- Prepare the meetings (questions, ideas), keep timing
- Speak up. What feedback you need
- It is normal to have phases of push and pull



Planification is key

"Your life will be no better than the plans you make and the action you take. You are the architect and builder of your own life, fortune, destiny."

Alfred A. Montapert

Your life will be no better than the plans you make and the action you take. You are the architect and builder of your own life, fortune, destiny.

Alfred A. Montapert



Everybody is an individual

- ❖ Supervisors also need mentorship and training
- ❖ We want, and need, the student to succeed
- ❖ We want to develop the researcher, not just the research
- ❖ Help us to help you

